Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Asieris and BeiGene to Test Combination Therapy for Bladder Cancer

publication date: May 6, 2021

Shanghai's Asieris Pharma and Beijing's BeiGene plan to test a combination of Asieris' MetAP2 inhibitor and BeiGene's PD-L1 inhibitor in bladder cancer patients. Asieris' APL-1202 is an oral drug that has anti-angiogenic, anti-tumor effects and also modulates the tumor immune microenvironment. BeiGene's tislelizumab binds PD-1 to restore an immune response for cancer. The Phase I/II trial will test the safety and efficacy of the combination in patients with muscle invasive bladder cancer (MIBC). Asieris plans to submit INDs in China and the US. More details....

Stock Symbol: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.